Keiferx LLC has entered into a research collaboration and option agreement with Amneal Pharmaceuticals Inc. to support the pre-IND development of KFRX-06, Keiferx’s brain-penetrant preclinical candidate designed to inhibit leucine-rich repeat kinase 2 (LRRK2), a gene strongly implicated in Parkinson’s disease biology.
Insilico Medicine Cayman Topco has announced a multiyear research and development collaboration with Laboratoires Servier SAS focused on identifying and developing novel therapeutics for challenging targets in oncology by leveraging Insilico’s proprietary AI platform, Pharma.AI.
Harbour Biomed and Yantai Lannacheng Biotechnology Co. Ltd. have entered into a long-term strategic collaboration to jointly advance the development of next-generation radionuclide-drug conjugates for the treatment of cancer.
Indupro Inc. has announced a strategic equity investment and research collaboration with Sanofi SA. The agreement with Sanofi includes the right of first negotiation for Indupro’s bispecific PD-1 agonist program.
Zealand Pharma A/S and OTR Therapeutics (Shanghai) Co. Ltd. have signed a multi-program strategic collaboration and license agreement to discover and develop novel therapeutics for metabolic diseases.
Oxford Biotherapeutics Ltd. has entered into a multiyear, multitarget strategic collaboration with GSK plc to discover novel antibody-based therapeutics for the treatment of cancer.
The collaboration brings together Relation’s AI-powered drug discovery platform and human data generation capabilities with Novartis’s expertise in immuno-dermatology to identify, validate and advance potential first-in-class targets in atopic diseases driven by immune dysregulation.
RSS
